SGLT-2 inhibitors in T2DM management: current position & future promise.

ESC Premium Access

SGLT-2 inhibitors in T2DM management: current position & future promise.

Session: SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Topic: Diabetes management

Speaker: Professor S. Inzucchi (New Haven, US)

Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Silvio Inzucchi

New Haven (United States of America)

5 presentations

0 follower

4 more presentations in this session

Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Speaker: Doctor D. Fitchett (Toronto, CA)

Access

Challenging CV Risk in diabetes: ready for a new approach?

Speaker: Professor J. Deanfield (London, GB)

Access

Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?

Speaker: Professor J. McMurray (Glasgow, GB)

Access

Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Speaker: Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access

Access the full session

SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Speakers: Professor S. Inzucchi, Doctor D. Fitchett, Professor J. Deanfield, Professor J. McMurray, Doctor D. Fitchett...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources